 |
|
|
| |
Older Patients Showed Similar Efficacy and Safety Results Compared With Younger Patients Over 96 Weeks in the Phase III ECHO and THRIVE Trials of Treatment-Naïve HIV-1-Infected Patients Treated With Rilpivirine or Efavirenz
|
| |
| |
Reported by Jules Levin
52nd ICAAC Sept 9-12 2012 SF
Robert Ryan,1 Yaswant K. Dayaram,2 Deborah Schaible,2 Bruce Coate,1 David Anderson2
1Janssen Research & Development, Titusville, NJ, USA; 2Janssen Services, LLC, Titusville, NJ, USA
References
1. Molina JM, et al. Lancet. 2011;378:238-246. 2. Cohen CJ, et al. Lancet. 2011;378:229-237. 3. Cohen CJ, et al. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Rome, Italy; July 17-20, 2011. Abstract TULBPE032. 4. Justice AC. Curr HIV/AIDS Rep. 2010;7:69-76. 5. Kirk JB, Goetz MB. J Am Geriatr Soc. 2009;57:2129-2138. 6. Centers for Disease Control and Prevention. October 26, 2010. www.cdc.gov/hiv/ehap/resources/fyi/102010/index.htm. Accessed August 9, 2012. 7. Blanco JR, et al. AIDS Rev. 2010;12:218-230. 8. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: Variation by age. AIDS.
2008;22:1463-1473. 9. Mussini C, et al. AIDS. 2008;22:2461-2469. 10. Tambuyzer L, et al. Antivir Ther. 2009;14:103-109. 11. Data on File. Janssen Therapeutics. 12. Wasserman P, et al. AIDS Patient Care STDs. 2010;24:223-237. 13. Dao CN, et al. Clin Infect Dis. 2011;52:396-405. 14. Herzmann C, et al. AIDS. 2009;23:274-275. 15. Brown TT, et al. Antivir Ther. 2010;15:425-429.
|
| |
|
|
|
|
|
